Experimental Dual-Target cell therapy for tough lymphoma shows early promise but study halted

NCT ID NCT06295549

First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 18 times

Summary

This early-phase trial tested a new cell therapy called LUCAR-G39P for people with B-cell non-Hodgkin lymphoma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target two markers (CD19 and CD20) on cancer cells. The study aimed to check safety and find the right dose, but it was terminated early after enrolling only 11 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, 226001, China

  • Beijing Gobroad Hosptial

    Beijing, 102206, China

  • Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

    Nanjin, Jiangsu, 210029, China

Conditions

Explore the condition pages connected to this study.